Novel Endpoints in Clinical Trials in Brazil

Clinical Trials in: Mexico, Argentina, Colombia and Brazil.

Locally-Based, Full Service CRO

Contact us today to learn more.

+ 0
Sites Throughout LATAM
+ 200
Patients in our network
+ 0
Conducted Studies
0 %
Lost-to-Follow Up rate
As a leading CRO in LATAM, we specialize in supporting clinical trials throughout the region. Our extensive experience and broad network of clinical sites enable us to execute trials with speed and efficiency, ensuring high patient recruitment and retention rates.

Novel Endpoints in Clinical Trials in Brazil

Novel Endpoints in Clinical Trials in Brazil – CRO LATAM

The world of medical research is undergoing a profound transformation, with an increasing emphasis on patient-centered care and personalized medicine. At the heart of this transformation lies the concept of novel endpoints in clinical trials—innovative approaches to measuring the effectiveness of medical interventions beyond traditional markers.

In this blog post, we embark on a journey through Brazil’s dynamic landscape of medical research, exploring how the country is embracing novel endpoints to redefine the way clinical trials are conducted and revolutionizing patient care.

The Evolution of Clinical Trial Endpoints

Historically, clinical trials have relied on conventional endpoints, such as survival rates and disease progression, to gauge the success of new treatments. While these measures have been instrumental in advancing medical knowledge, they often provide only a limited view of a patient’s overall well-being. Novel endpoints, however, represent a paradigm shift in clinical research.

These endpoints encompass a wide spectrum of outcome measures, including patient-reported outcomes (PROs), quality of life assessments, symptom relief, and functional status. By incorporating these measures, researchers can capture a more comprehensive understanding of how treatments impact patients’ lives.

Brazil’s Thriving Medical Research Landscape

Brazil has emerged as a prominent player in the global medical research arena, boasting a robust healthcare infrastructure, skilled professionals, and a diverse patient population. Regulatory agencies such as the National Health Surveillance Agency (ANVISA) have recognized the significance of novel endpoints and their potential to enhance clinical trial outcomes.

This forward-thinking approach has positioned Brazil as an attractive destination for both domestic and international researchers seeking to explore innovative methodologies.

The Promise of Novel Endpoints in Brazil

The integration of novel endpoints in clinical trials within Brazil offers a multitude of benefits. Firstly, it reinforces the country’s position as a frontrunner in patient-centered research, fostering collaborations between local experts and global partners. These collaborations not only contribute to scientific advancements but also drive economic growth and knowledge exchange.

Secondly, Brazil’s rich cultural and ethnic diversity makes it an ideal setting for studying the effects of medical interventions across various demographic groups. By incorporating novel endpoints, researchers can obtain insights that are more reflective of real-world patient experiences, ultimately leading to more effective and tailored treatments.

Furthermore, the utilization of novel endpoints aligns seamlessly with the global shift towards personalized medicine. Tailoring treatments to individual patient needs necessitates a deep understanding of how interventions impact patients’ lives beyond clinical markers. This approach can lead to more informed healthcare decisions and improved patient outcomes.

Novel Endpoints in Clinical Trials in Brazil

Novel Endpoints in Clinical Trials in Brazil

Novel Endpoints in Clinical Trials in Brazil

Challenges and Considerations

While the incorporation of novel endpoints holds great promise, it also presents challenges that must be addressed. Ensuring the validity and reliability of patient-reported outcomes is crucial, as subjective measures can be influenced by various factors. Standardizing data collection methods and establishing clear guidelines for endpoint assessment are essential to maintain the credibility of trial results.

Additionally, effective communication and collaboration among researchers, regulatory bodies, healthcare providers, and patients are paramount. Educating stakeholders about the significance of novel endpoints and their potential to revolutionize medical research can foster a supportive environment for their implementation.


Brazil stands at the forefront of a transformative era in medical research, championing the integration of novel endpoints in clinical trials. This patient-centric approach is reshaping the landscape of clinical research, offering a more holistic and nuanced understanding of treatment impacts.

As Brazil’s healthcare infrastructure evolves and its reputation as a hub for innovative research grows, the nation is poised to shape the future of healthcare on a global scale.

By embracing novel endpoints, Brazil not only contributes to advancements in medical science but also prioritizes the well-being of its population. This commitment to patient-centered care has the potential to revolutionize healthcare practices, leading to improved treatment outcomes, enhanced quality of life, and a brighter future for patients both within the country and beyond its borders.

Novel Endpoints in Clinical Trials in Brazil

Source: Duke Clinical Research Institute

Welcome to Cohortias!

of Latin America

Simplify Your Clinical Trials with Our Expert Infrastructure in Latin America

Say goodbye to the complex, costly, and disorganized process of conducting clinical trials. Our infrastructure in Latin America streamlines the launch of studies and ensures adherence to international standards. Schedule a call with us today to discover the path to simplified clinical research in Latin America.

Novel Endpoints in Clinical Trials in Brazil

Explore What We Are Doing Better

We define ourselves as a unique team, capable of blending our academic background with a global business mindset to bring the highest standard of quality and operational excellence into clinical research in Latin America.

Early Phase Trials

- First-in-Human Studies.
- Get to patients faster, no IND necessary.
- Valid data for FDA submission.

Rescue Studies

- Regain lost time and boost patient recruitment.
- We work alongside Global CROs to get studies back on track.
- More than 200 sites available.

Phase II & III Trials

- Full-Service Clinical Outsourcing.
- Proven infrastructure that can handle any trial.
- Local Regulatory Experts
- Wide network of sites and physicians.

Medical Devices

- A fast-track platform that will meet your timeline.
- We take care of everything, from shipping requirements all the way to data collection.
Novel Endpoints in Clinical Trials in Brazil

Full Service CRO in LATAM

Outsourcing Clinical Trials to Latin America

Unlock the advantages and opportunities of outsourcing clinical trials to Latin America. Diverse patient population, streamlined regulations, and cost-effectiveness

Lower Operating Costs

From lower labor costs to lower costs for rent, utilities, and equipment, you can save money on your clinical trial budget while still ensuring the quality of your trial

Access to Emerging Markets

Latin America offers access to emerging markets, providing an opportunity for pharmaceutical companies to expand their reach and reach new patient populations.

Novel Endpoints in Clinical Trials in Brazil

Cohortias is redefining Clinical Research in Latin America

We are committed to become leaders in providing clinical research services in Latin America. Here at Cohortias, we combine our academic roots, proven experience and a large pool of patients from an extensive network of sites.

Our main purpose is to deliver high quality data.

Novel Endpoints in Clinical Trials in Brazil

Clinical Research in Latin America

Cohortias has built an extensive and highly reputable network of clinical sites which can access patients in a timely manner and operate within a standard-of-care comparable to the U.S. healthcare system.


  • Site Management

  • Data Management

  • Site Selection

  • Regulatory Submissions

  • Clinical Monitoring

  • Protocol Development


Beta Trials Platform

  • First-in-human studies

Medical Devices

  • Pilot and Pivotal Device Studies

Phases I – III

  • We partner with our clients to bring their products in a fast and efficient manner to the market with the highest quality standards


  • Diabetes/Metabolic Syndromes
  • Infectious Diseases
  • Cardiovascular
  • Neurology
  • Respiratory
  • Oncology

Novel Endpoints in Clinical Trials in Brazil

Clinical Research in Latin America

Academic Leadership and Extensive Clinical Site Network for Efficient Clinical Trials

  • Our peer-to-peer management approach guarantees high patient recruitment and retention in any clinical trial

High Speed Execution

  • We offer the quickest start-up times in each country.
  • Efficient Clinical Site Selection and Contracting.
  • Benefit from our extensive network of clinical sites and streamlined contracting process.

Operational Excellence

  • Proven record of delivering rescue studies, we consistently exceed industry performance standards.
  • Our team provides efficient query resolution to keep your trial on track.

Business Insight and Flexibility

  • We offer innovative pricing models and short lines of communication to ensure maximum flexibility and cost-effectiveness.
  • At Cohortias, we prioritize  short lines of communication to ensure efficient collaboration.
  • Swift adaptation to changes in the trial landscape to keep your study on schedule.

Novel Endpoints in Clinical Trials in Brazil

We provide our services with offices in:

Colombia &

Daniela Maresca
Daniela Maresca | Country Lead Argentina
Martín Hernández-Torre | CMO
Maritza Rojas | CRA II
Pedro Alvarez | Business Development Manager
Samantha Rodriguez Cohortias
Samantha Rdz. | Start-Up Manager
Novel Endpoints in Clinical Trials in Brazil

The Cohortias Team

Novel Endpoints in Clinical Trials in Brazil

As the largest South American Contract research Organization, we know the Advantages and Challenges Of the Region

Let Us Guide You Through The Latin American Clinical Research Landscape

Novel Endpoints in Clinical Trials in Brazil

Network & Partnerships